ELITE Marketing Team Sunovion Pharmaceuticals, Inc.

Sunovion Respiratory Marketing Team

Sunovion Pharmaceuticals, Inc.

Denise Strauss, VP, Head of Marketing

Michael Gaines, Executive Director, Head of Respiratory Portfolio

Gerard Hernandez, Senior Director

Alex Marichal, Senior Director

Henry McMillan, Senior Director

Katie Marino, Director

Bryan Parker, Director

Scott Ellis, Director

Corey MacGregor, Associate Director

Sara Zwicker, Associate Director

Caesar Ruivivar, Associate Director

Daniel Yi, Associate Director

Yoshika Nayak, Associate Director

Dianel Yunes, Senior Product Manager

Terry McElhiney, Senior Administrative Assistant


Top row (left to right): Bryan Parker, Alex Marichal, Dan Yi, and Henry McMillan. Middle row: Scott Ellis, Michael Gaines, Gerard Hernandez, and Caesar Ruivivar. Bottom row: Terry McElhiney, Sara Zwicker, Dianel Yunes, Katie Marino, and Yoshika Nayak.

Commercializing Innovative COPD Products

The Sunovion Respiratory Marketing Team is comprised of a growing number of hardworking, passionate brand experts, all of whom contribute unique expertise and perspective. Just three months into the year, the team has doubled in size from seven to 14 under Michael Gaines’s leadership, and tackled the first of four brand launches for 2017.

For more than 10 years, Sunovion Respiratory has been best known for its market leading nebulized long-acting beta2-adrenergic agonist (LABA). As the brand got older, it easily could have lost its shine—but thanks to this creative and resourceful brand team, product sales have grown to new heights due to the exploration of channels that had never been considered before.

Three million patients are hospitalized each year due to COPD-related exacerbations, some of whom then spend time in long-term care (LTC) facilities. With this in mind, the Sunovion team has made it a priority to create growth opportunities across diverse channels, and it’s paid off. In 2016, this product was the sixth best-selling COPD product. And, as if that weren’t enough, Sunovion is seeking approval of the first and only nebulized long-acting muscarinic antagonist (LAMA) for COPD in the later this year.

Most recently, Sunovion acquired three handheld inhaler products and is actively promoting one, with two other launches to follow later this year. These introduce an additional LABA option, a LAMA choice, and a fixed-dose treatment that delivers a LABA and LAMA combination through a single device.

This robust portfolio of products will enter a competitive and crowded market. Luckily, the Sunovion team has the passion, commitment, and expertise to drive these brands to success.


You May Also Like

ELITE Transformational Leader Kristie Kuhl of Finn Partners

Kristie Kuhl Senior Partner Finn Partners A PR Healthcare Leader After just launching a ...

ELITE Disrupter Stephen Cannata of Iroko Pharmaceuticals LLC

Stephen Cannata Director, Marketing Iroko Pharmaceuticals LLC   Bringing NSAID Risks to Light Stephen ...

ELITE Strategist Lane Wilson of Sanofi-Genzyme

Lane Wilson Associate Vice President, Brand Head Dupilumab Respiratory Sanofi-Genzyme   The Instinctual Strategist ...